News
A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...
Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...
Cis-regulatory elements (CREs)—including promoters, enhancers, silencers, and insulators—are critical non-coding DNA ...
19h
Asianet Newsable on MSNKlotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene TherapyThe FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...
Our cells' identity is shaped by DNA tags called methylation. New tech, scDEEP-mC, maps these tags in single cells with ...
1d
InvestorsHub on MSNKlotho Neurosciences Shares Jump as FDA Grants Orphan Drug Status for ALS TherapyShares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...
Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...
Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced the results of ...
This study demonstrates that Setd2 overexpression rescues bivalent gene expression during zygotic genome activation (ZGA) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results